John D. Shulman is the Exec. Chairman at Petros Pharmaceuticals.
Mr Shulman is 58, he's been the Exec. Chairman of Petros Pharmaceuticals since . There are 1 older and 4 younger executives at Petros Pharmaceuticals. The oldest executive at Petros Pharmaceuticals, Inc. is Robert Weinstein, 61, who is the Interim Chief Financial Officer.
John's mailing address filed with the SEC is 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, , NEW YORK, NY, 10036.
Over the last 4 years, insiders at Petros Pharmaceuticals have traded over $0 worth of Petros Pharmaceuticals stock and bought 2,307,580 units worth $4,858,309 . The most active insiders traders include John Djcp Iii Sm Aiv, L.P.M..., Bruce Bernstein и Joshua Silverman. On average, Petros Pharmaceuticals executives and independent directors trade stock every 50 days with the average trade being worth of $74,319. The most recent stock trade was executed by Greg Bradley on 26 April 2023, trading 6,050 units of PTPI stock currently worth $2,112.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Petros Pharmaceuticals executives and other stock owners filed with the SEC include: